Denosumab (Xgeva®) has received EU approval for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours. The European Public Assessment Report (EPAR) for this product is available at the link below.